Gold ticks up but remains pressured by Fed rate caution, easing trade fears
William P. Quinn, President, CEO, and CFO of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), reported purchasing 125 shares of common stock at a price of $5.492, for a total value of $686. The company, currently valued at approximately $11.5 million, is trading below its InvestingPro Fair Value, suggesting potential upside opportunity despite challenging market conditions.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction occurred on June 6, 2025. In addition, Quinn acquired 40,000 shares of common stock on October 22, 2025, at no cost, representing restricted stock units received as an award. These restricted stock units vest fully on September 15, 2026, contingent upon continued employment. While the company maintains strong liquidity with a current ratio of 3.11, InvestingPro analysis reveals 8 additional key financial indicators that could impact investment decisions.
In other recent news, Bolt Biotherapeutics announced a delay in the initial clinical data for its cancer immunotherapy candidate, BDC-4182, now expected in the third quarter of 2026. This delay comes as the company modifies its clinical trial protocol to incorporate step-up dosing, following a strong immune response at initial dose levels in the ongoing Phase 1 study. Meanwhile, H.C. Wainwright initiated coverage on Bolt Biotherapeutics with a Buy rating, setting a price target of $7.00, highlighting BDC-4182’s unique approach as an immune-stimulating antibody conjugate.
In contrast, Leerink Partners lowered its price target for Bolt Biotherapeutics from $20.00 to $6.00, maintaining a Market Perform rating, due to concerns over the company’s limited cash runway. The firm noted that securing a partnership for BDC-3042, another of Bolt’s assets, is critical in the near term. Additionally, Bolt Biotherapeutics has announced a significant workforce reduction, cutting its staff by half. These developments reflect the company’s strategic adjustments and ongoing challenges in its drug development efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.